Choose your preferred way to stay informed of new case launches and settlement deadlines
Ovid issued a press release on June 17, 2024, announcing that “Takeda’s Skyline study in Dravet syndrome narrowly missed its primary endpoint of reduction in convulsive seizure frequency” and that “Takeda’s Skyway study in Lennox-Gastaut syndrome missed its primary endpoint of reduction in major motor drop seizures[.]” Following this news, Ovid’s stock price dropped over 28% on June 17, 2024.
In order to be eligible to join the OVID class action lawsuit, you must have incurred a loss on shares of Ovid purchased during the class period listed above.
TOP
